Acadian Asset Management’s Cytokinetics CYTK Stock Holding History

Acadian Asset Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$81K	Buy	+952	New	+$68.4K	﹤0.01%	1792
2026 Q1	–	Sell	-2,541	Closed	-$160K	–	2068
2025 Q4	$160K	Buy	+2,541	New	+$158K	﹤0.01%	1578
2024 Q4	–	Sell	-280	Closed	-$14K	–	1747
2024 Q3	$14K	Buy	+280	New	+$15.6K	﹤0.01%	2016
2018 Q1	–	Sell	-84,158	Closed	-$687K	–	1700
2017 Q4	$687K	Sell	84,158 -314,919	-79%	-$3.58M	﹤0.01%	761
2017 Q3	$5.79M	Sell	399,077 -367,186	-48%	-$5.02M	0.03%	350
2017 Q2	$9.27M	Buy	766,263 +431,457	+129%	+$6M	0.04%	291
2017 Q1	$4.3M	Buy	+334,806	New	+$3.91M	0.02%	442
2016 Q3	–	Sell	-334,284	Closed	-$3.17M	–	1444
2016 Q2	$3.17M	Sell	334,284 -889,162	-73%	-$7.3M	0.02%	452
2016 Q1	$8.62M	Buy	1,223,446 +53,134	+5%	+$388K	0.04%	295
2015 Q4	$12.2M	Buy	1,170,312 +1,079,774	+1,193%	+$10.6M	0.06%	267
2015 Q3	$606K	Sell	90,538 -40,276	-31%	-$275K	﹤0.01%	754
2015 Q2	$879K	Buy	130,814 +103,813	+384%	+$681K	﹤0.01%	703
2015 Q1	$183K	Buy	+27,001	New	+$202K	﹤0.01%	934
2013 Q4	–	Sell	-1,118	Closed	-$8K	–	1052
2013 Q3	$8K	Buy	+1,118	New	+$12K	﹤0.01%	945

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Acadian Asset Management's CYTK Position: Q2 2026 in Review

Acadian Asset Management opened a new position in Cytokinetics (CYTK) in Q2 2026: 952 shares worth $81K. The stake represents ﹤0.01% of the portfolio and ranks #1792 among its holdings. This is a return to the name: Acadian Asset Management previously reported a position in CYTK as recently as Q4 2025.

Acadian Asset Management first reported a position in CYTK in Q3 2013 and has held it in 14 quarters since. The position peaked at $12.2M in Q4 2015. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Acadian Asset Management held 952 shares of Cytokinetics worth $81K as of Q2 2026.
Cytokinetics was a new Acadian Asset Management position in Q2 2026.
Cytokinetics made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #1792 holding.
Acadian Asset Management first reported a position in Cytokinetics in Q3 2013 and has held it in 14 quarters since.
Acadian Asset Management's Cytokinetics position peaked at $12.2M in Q4 2015.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.